Pfizer’s COVID-19 Vaccine Gains Singapore’s Approval: Expects First Doses End December

 

 

 

The giant pharmaceutical Pfizer and its partner BioNTech have gained one more important client worldwide as Singapore approves of its vaccine.

On Monday, Prime Minister Lee Hsien Loong said that his country would be receiving the shots by the year end and that he would be one of the early receivers of the vaccine.

“My colleagues and I, including the older ones, will be getting ourselves vaccinated early. This is to show you, especially seniors like me, that we believe the vaccines are safe,” Lee said in a broadcast.

Authorities also said that the country had signed purchase agreements with major vaccine producers well in advance and had also advanced early down payments to vaccine developers who showed promise such as Moderna and Sinovac. They also said that the government has kept aside more than a billion dollars for vaccines.

“We have acquired sufficient doses of all the vaccines for all Singaporeans and long-term residents,” the health ministry’s director of medical briefing, Kenneth Mak, informed media at a recent briefing.

Prime Minister Lee also said that they would lift a few curbs put in place during the pandemic. From December 28, groups of eight will be allowed to get together in public, the earlier limit being five.

Singapore has had a tally of over 58,000 cases, out of which only 29 people died. This is one of the lowest fatality rates, worldwide. According to a Reuters tally, over 70 million people around the world have been infected by the coronavirus and there have been 1.61 million deaths.

Source CNBC

Image Wiki
Wikimedia


Follow us on Google news for more updates and News










PLEASE READ THE IMPORTANT DISCLOSURES BELOW.

This content is being provided to you for informational purposes only. The content has been prepared by third parties not affiliated with CWEB Inc, a business. This content and any information contained therein, does not constitute a recommendation by CWEB to buy, sell or hold any security, financial product or instrument referenced in the content. This information neither is, nor should be construed as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. CWEB Inc. does not offer or provide any opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make, and such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.

Unless stated otherwise, the web content provided by the CWEB family of companies is for educational purposes only. The information and tools provided neither are, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. or its affiliates. Unless stated otherwise, no information presented constitutes a recommendation by CWEB Inc. or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy.

Full Disclaimer

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.